| Keywords: |
cancer survival; protein expression; unclassified drug; gene mutation; exon; gene deletion; genetics; sequence deletion; squamous cell carcinoma; carcinoma, squamous cell; erlotinib; note; cancer radiotherapy; colorectal cancer; biological marker; metabolism; disease association; drug eruption; protein kinase inhibitor; epidermal growth factor receptor; gene locus; genetic association; genetic variability; editorial; receptor, epidermal growth factor; cetuximab; cancer resistance; monoclonal antibody; panitumumab; protein tyrosine kinase inhibitor; protein kinase inhibitors; oncogene; antibodies, monoclonal; drug antagonism; lung adenocarcinoma; head and neck neoplasms; drug response; gefitinib; receptor; receptor-like protein tyrosine phosphatases, class 2; oncogene k ras; gene dosage; k ras protein; b raf kinase; receptor gene; head and neck tumor; predictive value; egfr protein, human; epidermal growth factor receptor kinase inhibitor; heparin binding epidermal growth factor; head and neck squamous cell carcinoma; molecular pathology; epithelial mesenchymal transition; b raf gene; protein tyrosine phosphatase receptor s; receptor like protein tyrosine phosphatase; ptprs protein, human; protein tyrosine phosphatase receptor s gene
|
